IMM 23.0% 33.5¢ immutep limited

"Prima BioMed chief executive officer Martin Rogers told BTN he...

  1. 191 Posts.
    "Prima BioMed chief executive officer Martin Rogers told BTN he was confident the Phase 3 trial would help get the drug market approval after the company had positive results from its randomised Phase 2a and 2b studies."

    And then

    "The Phase 2b trial will involve 60 ovarian cancer patients from the United States and Australia"


    So they have had positive results from a trial they have not yet completed ???

    I know, its probably a typo or miss quote but thought I would throw it out there.

    No biggy

    Cheers



 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
33.5¢
Change
-0.100(23.0%)
Mkt cap ! $486.6M
Open High Low Value Volume
39.0¢ 40.0¢ 23.0¢ $16.23M 50.19M

Buyers (Bids)

No. Vol. Price($)
4 704297 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
33.5¢ 102135 2
View Market Depth
Last trade - 16.10pm 27/06/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.